Coexistence of Renin-independent Aldosterone Secretion and Multiple Endocrine Neoplasia Type 1 Within a Family.
independent aldosterone secretion
multiple endocrine neoplasia type 1
renin
Journal
Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
received:
09
07
2021
entrez:
21
2
2022
pubmed:
22
2
2022
medline:
22
2
2022
Statut:
epublish
Résumé
Primary aldosteronism (PA) is a state of renin-independent aldosterone secretion that can range from subclinical to overt. Some normotensive individuals for whom PA screening is not routinely recommended are reported to fulfill the loading test criterion used for the diagnosis of PA. Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by the development of various endocrine tumors. Cases of PA associated with MEN1 have been reported; however, there has been no previous report on renin-independent aldosterone secretion within a family with MEN1. Herein, we present the case of a normotensive family presenting with both MEN1 and renin-independent aldosterone secretion. A 49-year-old man was admitted to our hospital for PA evaluation owing to the plasma aldosterone concentration/plasma renin activity ratio being greater than the screening cut-off value; the patient was normotensive. The patient had a history of left nephrectomy and adrenalectomy for left renal carcinoma and adrenal tumor at the age of 39 years. Subsequently, he was diagnosed with MEN1 concurrent with primary hyperparathyroidism, insulinoma, and novel
Identifiants
pubmed: 35187382
doi: 10.1210/jendso/bvac009
pii: bvac009
pmc: PMC8852679
doi:
Types de publication
Case Reports
Langues
eng
Pagination
bvac009Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.
Références
J Clin Endocrinol Metab. 2018 Mar 1;103(3):900-908
pubmed: 29092077
Arch Surg. 2002 Jun;137(6):641-7
pubmed: 12049533
J Clin Endocrinol Metab. 2013 Apr;98(4):1409-16
pubmed: 23471976
Exp Clin Endocrinol Diabetes. 2020 Apr;128(4):246-254
pubmed: 31698477
Ann Intern Med. 2017 Nov 7;167(9):630-641
pubmed: 29052707
J Clin Endocrinol Metab. 2016 Nov;101(11):3989-3996
pubmed: 27428770
Hypertension. 2017 May;69(5):950-956
pubmed: 28289182
J Clin Endocrinol Metab. 2020 Dec 1;105(12):
pubmed: 32865201
Clin Endocrinol (Oxf). 2007 Oct;67(4):613-22
pubmed: 17590169
Hum Mutat. 2002 Jul;20(1):35-47
pubmed: 12112656
Radiographics. 2006 Mar-Apr;26(2):433-51
pubmed: 16549608
Clin Endocrinol (Oxf). 2012 Apr;76(4):533-9
pubmed: 21950691
Cancer Genet. 2016 Jan-Feb;209(1-2):36-41
pubmed: 26767918
J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011
pubmed: 22723327
Rinsho Byori. 2006 Nov;54(11):1157-63
pubmed: 17240838
J Am Coll Cardiol. 2017 Apr 11;69(14):1811-1820
pubmed: 28385310
Eur J Endocrinol. 2008 May;158(5):699-704
pubmed: 18426829
Eur J Endocrinol. 2012 Feb;166(2):269-79
pubmed: 22084155
Hypertension. 2011 Nov;58(5):797-803
pubmed: 21876069
Hum Mutat. 2008 Jan;29(1):22-32
pubmed: 17879353
Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50
pubmed: 29129575
J Clin Endocrinol Metab. 2016 May;101(5):1889-916
pubmed: 26934393
Ann Intern Med. 2020 Jul 7;173(1):10-20
pubmed: 32449886
Lancet Diabetes Endocrinol. 2018 Jan;6(1):51-59
pubmed: 29129576
Endocr J. 2011;58(9):711-21
pubmed: 21828936
J Endocr Soc. 2020 Jun 29;4(9):bvaa075
pubmed: 32783015
Endocr Rev. 2018 Dec 1;39(6):1057-1088
pubmed: 30124805
J Clin Endocrinol Metab. 2005 Sep;90(9):5070-6
pubmed: 15941863
World J Surg. 2002 Aug;26(8):891-6
pubmed: 12016472
Hypertension. 2011 Sep;58(3):341-6
pubmed: 21825220
Eur J Endocrinol. 2015 May;172(5):R191-203
pubmed: 25538205
J Clin Endocrinol Metab. 2002 Jul;87(7):3187-91
pubmed: 12107222
J Clin Endocrinol Metab. 2019 Sep 1;104(9):3726-3734
pubmed: 30865228
Arch Endocrinol Metab. 2019 Sep 02;63(5):516-523
pubmed: 31482957